PT  - JOURNAL ARTICLE
AU  - DIRK RADES
AU  - LENA SEHMISCH
AU  - STEFAN HUTTENLOCHER
AU  - OLIVER BLANK
AU  - DAGMAR HORNUNG
AU  - PATRICK TERHEYDEN
AU  - JAN GLIEMROTH
AU  - STEVEN E. SCHILD
TI  - Radiosurgery Alone for 1-3 Newly-diagnosed Brain Metastases from Melanoma: Impact of Dose on Treatment Outcomes
DP  - 2014 Sep 01
TA  - Anticancer Research
PG  - 5079--5082
VI  - 34
IP  - 9
4099  - http://ar.iiarjournals.org/content/34/9/5079.short
4100  - http://ar.iiarjournals.org/content/34/9/5079.full
SO  - Anticancer Res2014 Sep 01; 34
AB  - Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.